Cognitive Impairment Is Not a Requirement for Psychedelic Therapy: An Aripiprazole Dissociation Hypothesis

Mechanism: Aripiprazole's partial 5-HT2A antagonism selectively reduces frontal network desynchronization, thereby preserving executive function during psilocybin. Readout: Readout: Executive Function improves by 80% with aripiprazole, while mystical experience and therapeutic plasticity remain strong.

Aripiprazole Selectively Preserves Executive Function During High-Dose Psilocybin: A Dissociation Hypothesis The Observation A single individual on aripiprazole (2mg) and escitalopram (10mg) consumed approximately 14.7g of psilocybin mushrooms and reported a full mystical experience — vivid perceptual distortion, emotional depth, altered time perception — while maintaining functional executive capacity: coherent phone use, complex task completion, preserved meta-awareness throughout. This profile does not appear in the existing literature. Current reports describe aripiprazole either blocking the trip partially or weakening it. Preserved cognitive function during an intense experience has not been documented. The Hypothesis Aripiprazole's partial 5-HT2A antagonism selectively dampens the network desynchronization responsible for executive function collapse, while leaving intact — or even potentiating — the DMN disruption and neuroplastic signaling responsible for therapeutic benefit. In other words: the cognitive impairment and the therapeutic mechanism are separable, and aripiprazole may be a pharmacological scalpel that hits that seam. Mechanistic Basis Siegel et al. (2024, Nature) showed psilocybin causes massive, global network desynchronization — not uniform DMN suppression. The December 2025 Cell paper showed this rewiring is network-specific, selectively strengthening perceptual/DMN-to-subcortical routing. If aripiprazole's partial antagonism preferentially attenuates frontal desynchronization while leaving DMN-subcortical routing intact, you would predict exactly this profile: perceptual and emotional effects preserved, executive function spared. The 5-HT2A/mGlu2 heterodimer literature adds a second mechanism: aripiprazole's antagonism at monomeric 5-HT2A may leave heterodimeric signaling relatively intact, since heterodimer pharmacology differs from monomer pharmacology. Therapeutic neuroplasticity may run through the heterodimer; cognitive disruption through monomeric pathways. Predictions fMRI during aripiprazole + psilocybin would show: reduced frontal desynchronization relative to psilocybin-only controls, preserved or enhanced DMN-to-subcortical connectivity changes, and normal or above-baseline executive network coherence. Subjective experience ratings for perceptual intensity and emotional depth would not differ significantly from controls; executive function testing during the experience would show meaningful preservation. Falsification If fMRI shows equivalent global desynchronization to psilocybin-only conditions, the hypothesis fails — the cognitive preservation would require an alternative explanation. If the individual's reports reflect attenuated therapeutic benefit (no lasting mood improvement, no neuroplastic markers), then aripiprazole is simply blunting the experience, not dissociating the mechanisms. Why This Matters Millions of people on antipsychotics are currently excluded from psychedelic research. If aripiprazole selectively preserves executive function without eliminating therapeutic mechanism, it may enable a safer, more functional psychedelic modality — and reveal that cognitive disruption was never necessary for healing in the first place.